$4.58
4.91% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
US30049G1040
Symbol
EVOK
Sector
Industry

Evoke Pharma, Inc. Stock price

$4.58
-0.53 10.37% 1M
-1.04 18.53% 6M
-8.02 63.66% YTD
-10.66 69.95% 1Y
-139.42 96.82% 3Y
-153.82 97.11% 5Y
-876.70 99.48% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
+0.21 4.91%
ISIN
US30049G1040
Symbol
EVOK
Sector
Industry

Key metrics

Market capitalization $6.81m
Enterprise Value $470.00k
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.05
P/S ratio (TTM) P/S ratio 0.79
P/B ratio (TTM) P/B ratio 0.93
Revenue growth (TTM) Revenue growth 100.35%
Revenue (TTM) Revenue $8.62m
EBIT (operating result TTM) EBIT $-5.90m
Free Cash Flow (TTM) Free Cash Flow $-5.32m
Cash position $11.34m
EPS (TTM) EPS $-11.09
P/S forward 0.65
EV/Sales forward 0.02
Short interest 12.43%
Show more

Is Evoke Pharma, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Evoke Pharma, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Evoke Pharma, Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Evoke Pharma, Inc.:

Buy
100%

Financial data from Evoke Pharma, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
8.62 8.62
100% 100%
100%
- Direct Costs 0.30 0.30
9% 9%
3%
8.32 8.32
110% 110%
97%
- Selling and Administrative Expenses 14 14
29% 29%
165%
- Research and Development Expense 0.04 0.04
79% 79%
0%
-5.90 -5.90
19% 19%
-68%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -5.90 -5.90
19% 19%
-68%
Net Profit -6.15 -6.15
19% 19%
-71%

In millions USD.

Don't miss a Thing! We will send you all news about Evoke Pharma, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Evoke Pharma, Inc. Stock News

Neutral
Business Wire
one day ago
LOS ANGELES--(BUSINESS WIRE)--InvestCloud, a global leader in wealth technology, announced a strategic partnership with Registered Investment Adviser (RIA) Evoke Advisors (Evoke) to transform their digital experience. With InvestCloud's Client Experience, Evoke's clients, prospects, and third-party intermediaries will benefit from a significantly elevated and differentiated branded experience t...
Neutral
GlobeNewsWire
8 days ago
GIMOTI third quarter net product sales of $2.7 million, highest quarterly revenue ever with a 70% increase year-over-year
Positive
Proactive Investors
16 days ago
Shares in bookmakers galloped higher after the UK Budget, led by Ladbrokes and Coral owner Entain PLC (LSE:ENT), which rose over 8%, and William Hill owner Evoke PLC, rising 12%. Paddy Power and Betfair owner Flutter Entertainment PLC (LSE:FLTR) also rose 6%.
More Evoke Pharma, Inc. News

Company Profile

Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. It develops Gimoti, with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The company was founded by Matthew J. D'Onofrio, Cam L. Garner, Scott L. Glenn, and David A. Gonyer in January 2007 and is headquartered in Solana Beach, CA.

Head office United States
CEO Matthew D'Onofrio
Employees 4
Founded 2007
Website www.evokepharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today